-
Continuous innovation Coatings companies are turning aside new opportunities from their competitors
Time of Update: 2021-02-03
while the continued innovation of paint makers has helped them shake off their rivals, the downstream furniture industry is shuffleing, and the happiness index of furniture factory owners and dealers is falling to an all-time high.
-
Meet a competitor? PPG raised its bid for Dregurira to nearly $10 billion
Time of Update: 2021-01-12
On January 5th PPG Industries, Inc. and Tikkurila Oyj jointly announced that they had signed a new agreement to make changes to the previously announced merger agreement. the changes, PPG raised its offer for Mr DiGurira from 25 euros
-
Priced at 2.37 million yuan/year, SMA therapeutic drug Spinraza has welcomed a new competitor.
Time of Update: 2020-08-23
the drug has been approved for the treatment of infants and adults over 2 months of age with spinal muscular dystrophy (SMA).
-
Another Adamu monoanti-biosimilar drug was approved for intensive admission by the drug King Xiumeile competitors.
Time of Update: 2020-07-22
it is understood that the patent of the ® of Sumerano expires in the United States, China and Europe in 2016-2018, and its monopoly in the global market is gradually being challenged by biosimilars.
-
Moxifloxacin's gathering and adding competitors Bayer and dongyangyao
Time of Update: 2020-01-08
On January 8, Huabang Health announced that Chongqing Huabang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Huabang Pharmaceutical Co., Ltd., had recently
-
Baiji Shenzhou baize'an has been approved for listing, and there are 4 domestic PD-1 competitors
Time of Update: 2019-12-30
[industry trends of pharmaceutical network] on December 28, Baiji Shenzhou announced that the anti-PD-1 antibody drug baizean (general name: tirelizumab injection) had been
-
innovative anesthetic is coming; proton pump inhibitor is facing new competitors
Time of Update: 2019-12-23
Highlights: 1
New drug for rare diseases - aga β for injection is on the market in China! 2
Hengrui's first innovative anesthetic, rimazolom, will be approved
-
[Yao Kejun] the approval of PD-1 tirizumab in Baiji Shenzhou is on the way; this product has many competitors, and Hengrui wins the first imitation
Time of Update: 2019-12-09
This week's highlights: Baiji Shenzhou PD-1 is "in the process of approval" for the listing application of rilizumab; Hengrui celecoxib is the first to prevent the attack; Tonghua
-
7 4 + 7 varieties open the price reduction storm! 12 new competitors have entered the market
Time of Update: 2019-08-13
According to incomplete statistics, 7 "4 + 7" varieties in the near future have enterprises actively applied for price reduction, or to prepare for the purchase of the second tire volume.
-
[good medicine record] consistency evaluation weekly trends: hot varieties add competitors, 1
Time of Update: 2019-07-29
According to the pharmaceutical intelligence data, there are 66 market approvals for amlodipine besylate tablets in China, involving 60 manufacturers, that is to say, 60 enterprises need to do consistency evaluation.
-
Four years later, another domestic competitor came to US $7 billion
Time of Update: 2019-05-22
On May 21, according to the official website of the drug evaluation center of the State Drug Administration, Qilu pharmaceutical's application for the listing of inarcept
-
In the next few years, it may be difficult for MSD to meet its competitors
Time of Update: 2018-12-07
In terms of animal health products, MSD provides nearly 40 kinds of animal health products to the Chinese market to prevent, treat and control diseases of poultry and pets.
-
The declaration of volume purchase will be closed! 8 billion new competitors
Time of Update: 2018-11-28
In early November, the "4 + 7 urban drug centralized procurement document" was released to the public, and the volume procurement officially entered the sprint stage
-
Diabetes market changes! 2018 domestic competitors vs foreign leaders, who will win?
Time of Update: 2018-06-20
Metformin ranks the second in the market scale of oral antidiabetic drugs with a sales volume of 5.68 billion yuan in 2017, up 5.4% from 2017.
-
[yaogajun] the first "Gleevec" passed the consistency evaluation, adding another competitor
Time of Update: 2018-06-11
According to pharmaceutical intelligence data, at present, there are three domestic enterprises that have obtained the production approval documents of imatinib mesylate, including Zhengda Tianqing capsule, Jiangsu Haosen and Ouyi tablet.
-
What are the strong competitors of domestic generic drugs in 2018?
Time of Update: 2018-03-04
In 2017, the blowout of class 1 new drugs was "not surprising"
However, the follow-up of class 1 new drugs is generic drugs
In this issue, Xiaobian will lead
-
Drug retail market releases chain drugstores or becomes a strong competitor
Time of Update: 2017-08-29
[market analysis of China Pharmaceutical network] with the promotion of medical reform policy and the outflow of prescription drugs, the retail market capacity of drugs will be extremely broad in the future.
-
Analysis of the global best-selling drug Top50 and domestic competitors in 2014
Time of Update: 2015-10-23
Source: Medical Economics Report October 23, 2015 according to the statistics of evaluatepharm, the total sales volume of the top 50 best selling drugs in the world in 2014 reached
-
Liu Dianbo: how do Chinese pharmaceutical companies move from competitors in the era of internationalization 3.0
Time of Update: 2015-04-08
Source: bioexploration 2015-4-8 China Healthcare Investment Summit (CHIC) held by Fidelity Asia venture capital and vivo capital and hosted by lychee group on April 1, 2015 ）Held
-
Car-t competition: Novartis competitor Juno plans IPO of $191 million to accelerate clinical projects
Time of Update: 2014-12-11
Source: Biovalley, December 11, 2014, car-t therapy represents the most advanced cancer immunotherapy technology, has made great success in related clinical trials, has become one
